Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.

PMID:
29891538
2.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

3.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B.

J Allergy Clin Immunol. 2014 Jan;133(1):121-9.e1-2. doi: 10.1016/j.jaci.2013.05.032. Epub 2013 Jul 16.

PMID:
23870670
4.

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.

DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJF.

Allergy Asthma Proc. 2011 Nov 1;32(6):466. No abstract available.

PMID:
29165203
5.

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.

DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ.

Allergy Asthma Proc. 2011 May-Jun;32(3):239-47. doi: 10.2500/aap.2011.32.3453. Epub 2011 Apr 29. Erratum in: Allergy Asthma Proc. 2012 Nov-Dec;32(6):466.

PMID:
21535913
6.

Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor.

Holdich T, Sawyer J.

Expert Opin Pharmacother. 2008 Aug;9(12):2021-5. doi: 10.1517/14656566.9.12.2021 .

PMID:
18671458
7.

Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection.

Cahn P, Rolon M, Cassetti I, Shiveley L, Holdich T, Sawyer J.

Clin Drug Investig. 2008;28(2):129-38.

PMID:
18211121
8.
9.
10.

Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis.

Brodie MJ, Wroe SJ, Dean AD, Holdich TA, Whitehead J, Stevens JW.

Epilepsy Behav. 2002 Apr;3(2):140-146.

PMID:
12609415
11.

Remacemide versus carbamazepine in newly diagnosed epilepsy.

Whitehead J, Stevens J, Brodie M, Wroe S, Dean A, Holdich T.

Epilepsy Behav. 2002 Aug;3(4):405-406. No abstract available.

PMID:
12609343
12.

A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment.

Devinsky O, Vazquez B, Faught E, Leppik IE, Pellock JM, Schachter S, Alderfer V, Holdich TA.

Seizure. 2002 Sep;11(6):371-6.

13.

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen.

Chadwick DW, Betts TA, Boddie HG, Crawford PM, Lindstrom P, Newman PK, Soryal I, Wroe S, Holdich TA.

Seizure. 2002 Mar;11(2):114-23.

14.

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.

Jones MW, Blume WT, Guberman A, Lee MA, Pillay N, Weaver DF, Veloso F, Holdich TA.

Seizure. 2002 Mar;11(2):104-13.

15.
16.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.

Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B; Parkinson Study Group.

Neurology. 2001 Feb 27;56(4):455-62.

PMID:
11222787
17.

Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers.

Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TA, Posner J.

Antimicrob Agents Chemother. 1995 Jan;39(1):20-7.

18.

Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J.

Br J Clin Pharmacol. 1994 Jan;37(1):13-20.

19.

566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.

Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DB, Pudney M, Randall AW, Latter VS.

Drugs Exp Clin Res. 1991;17(9):427-35.

PMID:
1822435
20.

Transcutaneous oxygen tension during exercise in patients with claudication.

Holdich TA, Reddy PJ, Walker RT, Dormandy JA.

Br Med J (Clin Res Ed). 1986 Jun 21;292(6536):1625-8.

Supplemental Content

Loading ...
Support Center